Wuhan Desheng Biochemical Technology Co., Ltd

Starting from April 28, 2026, the inter provincial alliance led by Jiangxi Province to purchase sugar metabolism and other biochemical testing reagents in bulk will be officially implemented in multiple regions. This centralized procurement covers 35 commonly used clinical biochemical testing items, including glucose metabolism, liver function, kidney function, myocardial enzymes, pancreas, etc. The selected products have an average reduction of 70%, and some products have a reduction of over 98%. Biochemical diagnosis, a core sub field of in vitro diagnostics, has been fully included in the scope of centralized procurement. As a core supplier in the field of in vitro diagnostic (IVD) reagent raw materials, Hubei Xindesheng believes that the comprehensive implementation of centralized procurement is reshaping the competitive landscape of the industry, and high-quality, cost-effective, and highly stable diagnostic raw materials will play a key role in the new market environment. 1．Core data of centralized procurement: 154 companies selected, deep reshaping of price system According to the selection results released by the Jiangxi Provincial Medical Insurance Bureau, a total of 2314 specifications of biochemical testing reagents for sugar metabolism and other biochemical testing were selected from 154 enterprises through the inter provincial alliance procurement, with a proposed selection rate of 85%. The 35 types of testing items covered by the centralized procurement precisely focus on the diagnosis and treatment testing needs of chronic diseases such as diabetes, liver and kidney diseases, cardiovascular diseases, etc. In terms of price, this centralized procurement is unprecedented. The selected products have an average reduction of 70%, with some products experiencing a reduction of over 98%. 42 companies have quoted prices below 0.1 yuan per person for ion trace elements and sugar metabolism products. Among them, Roche Diagnostics, Beckman Coulter, Siemens Healthineers, Mindray Medical, and New Industries' "Calcium (CA)" products were all selected at a price of 0.07 yuan per person, New Industries' "Glucose (GLU)" was also selected at 0.07 yuan, and Roche Diagnostics' "Phosphorus (P)" was selected at 0.06 yuan. Some companies even quoted the lowest price of 0.03 yuan for the entire event. The procurement cycle for centralized procurement is 2 years, with the first year's procurement cycle from March 1, 2025 to February 28, 2026. As of now, public medical institutions in Ma'anshan, Tongling and other places in Anhui have fully launched the procurement and use of selected products. Relying on the price linkage mechanism of 26 provinces, the long-standing regional price differences have been effectively eliminated. 2．Industry impact: Cost pressure drives upstream raw material upgrades The comprehensive implementation of centralized procurement has had a profound impact on the IVD industry. Cost control capability has become the core competitiveness of downstream reagent production enterprises and medical institutions. According to industry analysis, centralized procurement has led to a change in the market size of approximately 7 billion yuan in the biochemical field. The categories covered by the three rounds of centralized procurement have accounted for about 90% of the biochemical IVD market. Under fierce price competition, 5 IVD companies and over 1400 product specifications have voluntarily withdrawn from the centralized procurement of liver function, kidney function, myocardial enzymes, and glucose metabolism biochemical reagents. Industry insiders point out that once the decline in the field of biochemical IVD exceeds 60%, manufacturers' profits will be severely impacted. In this context, the quality and cost efficiency of upstream raw materials have become key factors determining whether downstream reagent manufacturers can maintain positive cash flow after winning bids at low prices. As industry reports point out, centralized procurement forces midstream manufacturers to extend upstream and achieve self-developed and self-produced core raw materials or select cost-effective suppliers. The procurement cost and quality control of core raw materials have become key factors affecting competitiveness. The normalization of centralized procurement has made the prices of mid to low end biochemical reagents transparent, and enterprises that lack the ability to produce raw materials themselves or cannot effectively control raw material costs face direct clearance pressure. Hubei Xindesheng Material Technology Co., Ltd. has long focused on the field of IVD reagent raw materials, deeply cultivating the research and development, production, and sales of core products such as biological buffering agents, enzyme preparations, chromogenic substrates (chromogenic substrates), and blood collection tube additives. The company was formerly known as Wuhan Desheng Biochemical, established in 2005. After years of technological accumulation and continuous innovation, it has grown into a core enterprise in the field of IVD reagent raw materials in China. The company has completed the closed-loop process of two core products, EPS G7 amylase substrate and DGGR lipase substrate, and successfully connected the entire process from laboratory small-scale testing to kilogram scale mass production. The comprehensive implementation of inter provincial alliance centralized procurement of biochemical detection reagents such as sugar metabolism marks a new stage of "improving quality and controlling costs" in the biochemical diagnosis industry. For the IVD reagent raw material industry, the importance of quality stability, cost efficiency, and supply guarantee capability will be further highlighted. Hubei Xindesheng Material Technology Co., Ltd. will adhere to craftsmanship and quality, continuously increase research and development investment, empower the development of IVD in vitro diagnostic industry with more stable products, more professional technical support, and more competitive cost-effectiveness, and help the industry achieve high-quality development under the background of normalized centralized procurement.

On August 31st, Kangda New Materials disclosed its latest industrial layout progress. The company is making every effort to promote the construction of Dalian Qihua's 80000 tons/year electronic grade epoxy resin expansion project. The project has entered the civil construction stage and is expected to undergo equipment installation in the fourth quarter of 2026. The epoxy resin produced is mainly used in fields such as electronic materials, composite materials, functional coatings, and adhesives. 1．Behind the expansion of resin production: increasing the quantity of substrates and following up on products Resin is the foundation of the polymer materials industry. Whether it is epoxy resin, polyurethane resin or acrylic resin, their capacity expansion directly drives the improvement of downstream resin based product supply capacity and the expansion of application scenarios. Taking acrylic resin as an example. Acrylic resin has excellent weather resistance, light resistance, chemical resistance, adhesion and decorative properties, and is widely used in fields such as architectural coatings, industrial paints, automotive paints, inks, adhesives, textile coatings, etc. Polyacrylic acid and its derivatives can also be used in ion exchange resins and adhesives, as well as thickeners, dispersants, suspensions, and emulsifiers in the pharmaceutical and pigment industries. When the production capacity of upstream specialty resins continues to be released, fine products based on resins - whether it is serum separation gel used for medical testing or carbomer used in daily chemical and industrial fields - will have more abundant raw material guarantees and broader market space. 2．Two typical resin based fine products: serum separation gel and carbomer Hubei Xindesheng Material Technology Co., Ltd. has been deeply engaged in the fields of fine chemicals and biological raw materials for more than 20 years. The company's core products, serum separation gel and carbomer, are typical representatives of fine products based on resins. The serum separating gel is essentially an acrylic resin composite gel. As a key additive in blood collection tubes, serum separation gel directly determines the separation efficiency between serum/plasma and blood cells. The specific gravity of the serum separation gel from Hubei Xindesheng is precisely controlled within the range of 1.045-1.065 g/cm ³, which can accurately form layers during centrifugation; For special application scenarios such as PRP tubes, the company has also developed products with a specific weight of 1.068. The product has no heat source and is physiologically inert. After sterilization with gamma rays (8-25 kGy), there is no significant change in performance, and it has excellent resistance to hydrolysis and aging. At present, Hubei Xindesheng's serum separation gel has been widely used in the in vitro diagnostic industry. Carbomer is also a resin based product - made by crosslinking polyacrylic acid polymer with allyl sucrose or allyl pentaerythritol. It belongs to synthetic water-soluble polymers, mainly used as thickening agents, suspension aids, adhesives, and skeleton materials for controlled release formulations. Carbopol has good solubility and dispersibility, and is widely used in the preparation of products such as coatings, adhesives, dyes, and inks. Polyacrylic acid can also be used as a thickener, dispersant, flocculant, adhesive, and film-forming agent, widely used in industrial fields such as coatings, plastics, papermaking, textiles, rubber, food, medicine, cosmetics, and water treatment. Hubei Xindesheng's Carbomer series covers 940/980 and other models, and is used as thickening and gel forming agent in disposable alcohol gel and daily chemical products. Carbomer produced by the company is a white loose powder with strong moisture absorption and excellent gel forming ability. Whether it is serum separation gel or carbomer, their performance directly depends on the quality and process control level of upstream resin raw materials. The continuous expansion of special resin production capacity provides more abundant raw material guarantee and broader market space for the downstream resin based fine products industry. From serum separation gel to carbomer, Hubei Xindesheng Material Technology Co., Ltd. uses resin as the substrate and provides key functional products for industries such as in vitro diagnostics, daily chemical products, coatings, adhesives, etc. through continuous process optimization and quality control. We will continue to deepen our research and production of resin based fine products, providing stable quality services to every partner.

1.Carbopol solvent residue: a common quality challenge in the pharmaceutical and daily chemical industries Carbomer (polyacrylic acid resin) is an indispensable rheological modifier in the fields of medicine, personal care, and industry, with three core functions of thickening, suspension, and emulsification. However, due to the introduction of various organic solvents such as benzene, ethyl acetate, and cyclohexane in its preparation process, residual carbomer solvents have always been a key quality problem that troubles the industry. According to the 2025 edition of the Chinese Pharmacopoeia, the key limits for residual solvents in carbomer are: benzene should not exceed ≤ 2ppm, ethyl acetate should not exceed 0.5%, and cyclohexane should not exceed 0.3%. For Carbopol products applied in the fields of pharmaceutical excipients, high-end cosmetics, and medical devices, solvent residue control is directly related to product compliance and user safety. How to control residual solvents in Carbopol? This is a question that every Carbopol production technician is thinking about. Hubei Xindesheng Material Technology Co., Ltd., in collaboration with the Quality Department, has launched a special technical research and development project to address common challenges in this industry. 2.Technical Root Analysis of Carbopol Solvent Residue To fundamentally solve the problem of residual solvents in Carbopol, the New Desheng Technology Department and Quality Department have established a special research and development team to conduct a systematic investigation of the existing Carbopol production process. After multiple rounds of analysis and verification, the research team has identified the key factors affecting the residual Carbopol solvent, which mainly focus on the following aspects: (1) Selection of solvent system for polymerization stage Traditional carbomers (such as carbomer 940, carbomer 934, etc.) use benzene as the polymerization solvent, which poses a high risk of residual solvents. How to optimize the solvent system while ensuring polymerization efficiency is a key research topic. (2) The efficiency issue of washing process After polymerization, the crude carbomer still contains a large amount of unreacted solvents, initiators, polymerization inhibitors, and other residues. The traditional washing process has the problem of insufficient efficiency in removing these impurities. (3) Insufficient refinement of drying process Improper control of drying temperature and time may result in incomplete solvent evaporation or thermal discoloration of the product. Research has shown that when the drying temperature exceeds 120 ℃, the product will exhibit varying degrees of light yellow color. 3.Optimization of Carbopol Production Process: Stage Results After a long period of research and development, the special team has made breakthroughs in optimizing the production process of Carbopol: (1) Optimization and upgrade of Carbopol washing process The research team has systematically optimized the washing process of crude carbomer. Research has shown that washing newly prepared carbomer with ethanol aqueous solutions of different mass fractions can effectively remove residual initiators, inhibitors, and other impurities. The team further optimized parameters such as washing temperature, washing frequency, and solvent ratio, resulting in a significant increase in impurity removal rate. (2) Fine control of Carbopol drying process The research team has established the core process route of low-temperature vacuum drying, strictly controlling the drying temperature at a certain temperature. At the same time, a temperature time vacuum linkage control model was established to achieve precision and standardization of the carbomer drying process. (3) Establish a process control system for residual solvents in Carbopol The quality department has set up sampling and testing points for residual solvents in key processes such as aggregation, washing, and drying, achieving a transition from "terminal inspection" to "process control". (4) Improvement of Carbopol Solvent Residue Index After process optimization, the solvent residue of the company's carbomer was significantly reduced. The key residual solvent indicators such as ethyl acetate and cyclohexane have been stably controlled within the limits, and some indicators are better than the internal control standards. By optimizing the carbomer washing process, refining the drying process, and establishing a process control system, New Desheng has made substantial breakthroughs in controlling residual solvents in carbomer. The next article will focus on the synchronous upgrade of detection capabilities - providing a detailed introduction to the company's new gas chromatography (GC) equipment configuration, optimization of carbomer residual solvent detection methods, and improvement of quality control systems.

As of August 2026, all 66 domestic IVD listed companies have disclosed their semi annual reports. The three rankings of revenue, growth rate, and net profit show an unprecedented "misalignment" - some companies have seen revenue growth of over 30% but are still losing money, while others have seen a significant improvement in profits despite a decrease in revenue. Through this report card, a clear signal is being released: China's IVD has bid farewell to the stage of widespread growth relying on market expansion and officially entered the era of testing business quality. 1．Half year report 'misalignment': growth and profitability are decoupling According to the total revenue ranking, Fosun Pharma and Mindray lead with 20.442 billion yuan and 17.747 billion yuan respectively, but only 4 out of the top ten companies have achieved positive revenue growth, and most top companies have not yet escaped the pressure of industry adjustment. More noteworthy is the divergence between growth and profitability. Among the top ten companies in terms of total revenue growth rate, Re Jing, Kangwei Century, Wantai, Huada Intelligent Manufacturing, and Yirui are still in a loss making state; Pumen Technology's revenue increased by 19.15%, but its net profit decreased by 34.80%. On the other hand, Dean Diagnostics' net profit surged by 2160%, but profit growth mainly relied on cost reduction and efficiency improvement, as well as narrowing credit impairment losses - some companies' performance improvements were "saved" rather than "earned". Among the top ten companies in terms of net profit, only the top three companies have a combined net profit of nearly 9.6 billion yuan, accounting for 68.26% of the total net profit of 66 enterprises. The concentration of the top is extremely high, and on the loss making list, five companies including Oriental Biotechnology, Huada Intelligent Manufacturing, Wantai, Rejing, and Kehua have not crossed the breakeven line despite their positive revenue growth. 2． Why is it easy to increase income but difficult to increase profits? The normalization of centralized procurement, mutual recognition of inspection results, and DRG payment reform continue to exert multiple pressures on industry profits. In the first quarter of 2026, 43 out of 64 IVD companies were operating at a loss. When terminal reagent prices are continuously compressed, raw material costs - the largest variable cost in reagent production - become the key variable determining whether a company can make profits. Industry analysis indicates that the profit pool of the industrial chain is shifting towards upstream raw materials and downstream scale platforms. With midstream manufacturers facing extreme cost control pressure, their demand for localization of core raw materials such as enzymes, buffering agents, color substrates, etc. is unprecedentedly high. The upstream core raw materials are accelerating the breakthrough of import dependence, and the domestication rate of midstream instruments and reagents continues to rise. Mindray Medical acquired the globally renowned IVD raw material company, Hai Peptide Biotechnology, in 2021, achieving independent and controllable core technology in the field of chemiluminescence raw materials; The self-sufficiency rate of core raw materials for Mike Biology has increased to over 70%. The actions of top enterprises have already demonstrated that raw material autonomy is not just a bonus, but a bottom line for survival. 3．New Desheng's perspective: Where are we located? Hubei Xindesheng Material Technology Co., Ltd. has been deeply involved in the IVD reagent raw material track for 20 years, focusing on the research and production of core products such as biological buffering agents, enzyme preparations, color substrates, and blood collection tube additives. In 2026, the company was selected as a single champion enterprise in the manufacturing industry in Hubei Province. The data from the semi annual report confirms our long-term judgment: when terminal prices are pushed to the limit by centralized procurement, the quality and cost efficiency of upstream raw materials can truly help reagent manufacturers maintain their profit bottom line. Biological buffering agents: more than 50 products including Tris, HEPES, MOPS, etc., with a stable purity of over 99%. High purity means fewer inter batch differences and lower repeat detection rates - this is an implicit cost savings. Enzyme preparations: lactate dehydrogenase (LDH), uricase (UO), creatine kinase isoenzyme (CK-MB), etc., with high activity and stability, help reagent manufacturers achieve better detection performance with less raw material usage. Chromogenic substrates: TOOS, MAOS, ALPS, etc. benchmark against international standards; EPS-G7 amylase substrate and DGGR lipase substrate have achieved kilogram scale mass production - reagent manufacturers can get rid of import dependence and obtain stable and more cost-effective supply. Blood collection tube additives: heparin lithium, heparin sodium, EDTA dipotassium/tripotassium, serum separation gel, etc., covering the entire process of blood sample pretreatment. The company has two R&D and production bases in Gedian and Huanggang (70 acres), with an annual production capacity of 5000 tons for all categories. The truth revealed by 66 semi annual reports is that the industry has entered a stage of stock competition, where the competition is no longer about whose channels are wider and whose brands are louder, but whose supply chain is deeper, raw material costs are lower, and quality is more stable. For IVD reagent manufacturers, in an era where increasing revenue is easy but increasing profits is difficult, upstream raw materials are the "watershed". New Desheng will continue to focus on the research and production of IVD reagent raw materials, using higher quality and more cost-effective products to help partners build true cost barriers in the industry reshuffle. Hubei Xindesheng Material Technology Co., Ltd. - Focusing on IVD reagent raw materials to assist in accurate diagnosis